Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras ...

Mutation-directed targeted therapy in combination with a PD-L1 inhibitor “is a promising strategy” to extend survival in patients with anaplastic thyroid cancer, according to researchers.

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

with a BRAF gene mutation. The agency approved the medication, also known as encorafenib, to be used in combination with cetuximab, also known as Erbitux, and mFOLFOX6 chemotherapy for the ...

They found that BRAF mutations are present in a number of cancers, including approximately 50% of melanomas. They then went on to confirm mutated BRAF as an oncogene capable of driving the development ...

A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

with a BRAF gene mutation (present in 50% of melanoma cases), and PARP and PD-L1 inhibitors intended for breast cancer with a BRCA gene mutation or deficiency. The novel drug delivery system was ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) ...

with a BRAF gene mutation (present in 50% of melanoma cases), and PARP and PD-L1 inhibitors intended for breast cancer with a BRCA gene mutation or deficiency. The novel drug delivery system was ...